Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_assertion type Assertion NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_head.
- NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_assertion description "[Potentially druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladder carcinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenocarcinoma (1.6%), lung squamous cell carcinoma (2.3%) and thyroid carcinoma (8.7%), suggesting a potential for application of kinase inhibitors across tumor types.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_provenance.
- NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_assertion evidence source_evidence_literature NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_provenance.
- NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_assertion SIO_000772 25500544 NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_provenance.
- NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_assertion wasDerivedFrom befree-2016 NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_provenance.
- NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_assertion wasGeneratedBy ECO_0000203 NP1247367.RA5KsYFs7_6gg3UAPENF5uvBNM0zfnhIz8Rk9Q5rUIk8w130_provenance.